Last reviewed · How we verify
PLX3397
At a glance
| Generic name | PLX3397 |
|---|---|
| Also known as | Pexidartinib, Targeted therapy, pexidartinib, Plexxikon 3397 |
| Sponsor | Daiichi Sankyo Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... (PHASE1)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan (PHASE2)
- A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma (NA)
- A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT (PHASE3)
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PHASE1, PHASE2)
- CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors (PHASE1, PHASE2)
- Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PLX3397 CI brief — competitive landscape report
- PLX3397 updates RSS · CI watch RSS
- Daiichi Sankyo Co., Ltd. portfolio CI